The stock's fall snapped a five-day winning streak.

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer is talking about. Jim Cramer in a latest program on CNBC discussed ...

Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...